Case Report

Splenomegaly, Cardiomegaly, and Osteoporosis in a Child with Gaucher Disease

J. J. Sheth,1 C. M. Ankleshwaria,1 M. A. Mistri,1 N. Nanavaty,2 and S. J. Mehta3

1 Institute of Human Genetics, FRIGE House, Jodhpur Gam Road, Satellite, Ahmedabad 380015, India
2 Opp. Sanghvi High School, Naranpura, Ahmedabad 380014, India
3 Usha Deep Children Neurology and Epilepsy Clinic, 3rd Floor, Mansarovar Complex, Naranpura, Ahmedabad 380014, India

Correspondence should be addressed to J. J. Sheth, jshethad1@gmail.com

Received 13 July 2011; Accepted 8 August 2011

Academic Editors: D. Fischer and A. Gedalia

Copyright © 2011 J. J. Sheth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 15-month-old girl, born to the consanguineous parents, was referred with the sign of massive splenomegaly associated with thrombocytopenia and anemia. Plasma Chitotriosidase estimation was carried out as a screening test and was found to be normal with reduced activity of β-glucosidase in leucocytes suggestive of Gaucher disease. At the age of 4 years, severe osteoporosis and cardiomegaly with pulmonary congestion were observed in the child. Molecular analysis for GBA gene has revealed homozygous status for L444P (c.1448C) in the proband, whereas parents and two elder sisters were found to be heterozygote. Prenatal study during the fourth pregnancy was carried out from cultured chorionic villi for β-glucosidase, which was in the carrier range. Further confirmation of the carrier status was carried out from amniotic fluid DNA and was found to be heterozygous for L444P (c.1448C) in the GBA gene. This case demonstrates that children with the sign of splenomegaly with anemia and thrombocytopenia need to be screened for Gaucher disease, and molecular study can further help to confirm the heterozygous status, where prenatal study by enzyme investigation demonstrate heterozygous condition.

1. Introduction

Gaucher disease (GD) is an autosomal recessive sphingolipid disorder resulting from the accumulation of glucocerebroside in the cells of macrophage-monocyte system as a result of a deficiency in lysosomal enzyme β-glucosidase [glucocerebrosidase, E.C. 3.2.1.45], which is encoded by the GBA gene on chromosome-1 [1]. The three main clinical types have been delineated according to the absence (type 1, nonneuronopathic) or the presence (type 2, acute neuronopathic, and type 3, sub acute neuronopathic) of neurological involvement [2]. Glucosylceramide, the accumulated glycolipid, is primarily derived from the phagocytosis and degradation of senescent leukocytes and, to a lesser extent, from erythrocyte membranes. The glycolipid storage gives rise to the characteristic Gaucher cells, which are typically present in the bone marrow, liver, spleen, lungs, and other organs. This contributes to pancytopenia, massive hepatosplenomegaly, and at times diffuse infiltrative pulmonary disease. However, signs like anemia, severe splenomegaly, and hepatomegaly were observed more frequently in younger patients [3].

2. Case Report

A 15-month-old female child was referred to our centre with the clinical sign of massive splenomegaly associated with thrombocytopenia and anemia. She was delivered after full-term normal pregnancy. She had seizure immediately after 2 hours of birth and was kept under observation for a day. Development of the child was normal till 1 year of age. Later on, her parents noticed sporadic crying and regression of milestones especially when she stopped walking. Her two elder sisters were healthy, and there was no family history of blood transfusion, splenectomy, and recurrent jaundice. She was referred for plasma chitotriosidase estimation at the age of 15 months, which was 64.12 nmol/hr/mL plasma (normal range: 28.66–62.94 nmol/hr/mL plasma). Ultrasound scanning at 15 months showed the spleen of about 11-12 cm. No active bleeding, hepatomegaly, or lymphadenopathy was observed. X-ray of the pelvis with lower limbs was found to be normal. Subsequently, colour Doppler was carried out, which had shown huge splenomegaly with normal splenic echotexture and splenic vein measuring 4 mm at splenic
The most common signs and symptoms noted in GD are splenomegaly (95%), hepatomegaly (87%), radiological bone disease (81%), thrombocytopenia (50%), anemia (40%), growth retardation (34%), bone pain (27%), and bone crisis (9%). A skeletal manifestation is found more often in older children [3]. The femoral head and the femoral shaft are by far the most frequently involved sites in bone crisis. However, these episodes occur with some frequency in humeral heads, vertebral bodies, and ischium of pelvis [4]. In the present case, all these symptoms were observed and in addition osteoporosis and fracture in lower shaft tibia/fibula, severe osteoporosis with cortical irregularity and fracture were seen along the midshaft of the humerus. Cardiomegaly with pulmonary congestion was also observed at this time, and it is likely to occur due to frank infiltration of lungs by Gaucher cells [4].

Plasma chitotriosidase, which acts as a screening marker and shows marked elevated level in Gaucher disease, was found to be normal in present case [5]. This can be explained by the fact that 5-6% of the population who lack this enzyme as a result of genetic deficiency due to an expressive mutation in the human chitotriosidase gene that occurs with high polymorphic frequency and approximately one-third of patients with GD are heterozygous for this null allele, and thus the extent to which GD may increase the activity of chitotriosidase in the plasma is reduced in these individuals [6, 7]. Although β-Glucosidase activity in leucocytes or fibroblasts is the confirmative test for GD followed by mutation identification in GBA gene [8]. Our study is in accordance with this observation with significantly low activity of the enzyme in leucocytes followed by identification of L444P mutation in the proband. Identification of the genotype may help in predicting phenotypic expression, therapeutic response, and carrier screening for genetic counseling. Presence of L444P (c.1448C) homozygous status in the proband was useful in detecting carrier status in both parents, two unaffected sisters, and during prenatal counseling. Presence of L444P (c.1448C) homozygous status in the proband was useful in detecting carrier status in both parents, two unaffected sisters, and during prenatal diagnosis. This is one of the most common mutation observed in non-Jewish populations with a frequency of 31.43% and resulted in substitution of proline for leucine at position 444(L444P) [9]. This mutation was first found in neuronopathic form (Type I) [10].

It has been reported that nonneuronopathic GD is the most prevalent form (94%) and is differentiated from the acute neuronopathic (1%) and chronic neuronopathic (5%) forms by the absence of central nervous system involvement [3]. In the present report, hepatosplenomegaly, anemia, thrombocytopenia, osteoporosis, cardiomegaly, mild hypotonia, and homozygous for L444P (c.1448C) mutation and
normal central nervous system examination suggest Type-I Gaucher disease.

In such cases the long-term clinical picture is critical in light of data demonstrating that the efficacy of enzyme replacement therapy (ERT) with placental-derived preparation, alglucerase or the recombinant form, imiglucerase and substrate reduction therapy (e.g., miglustat) can prevent progressive manifestations of GD and completely or partly ameliorates disease-associated anemia, thrombocytopenia, organomegaly, bone pain, and bone crises [11].

As per our knowledge, this is the only case study from India where screening to confirmative molecular analysis has been carried out in the family. It clearly demonstrates that primary screening by plasma chitotriosidase followed by confirmative enzyme study of β-Glucosidase together with mutation identification can help the family to corroborate the prenatal and postnatal diagnosis for an early therapeutic approach, before irreversible clinical manifestation occurs.

**Authors’ Contribution**

J. J. Sheth was involved in the designing of the study and in preparation of paper. J. J. Sheth will act as a guarantor. C. M. Ankleshwaria and M. A. Mistri were involved in processing of sample and writing of paper; N. Nanavaty and S. J. Mehta were involved in clinical data collection.

**Conflict of Interests**

The authors declare that there is no conflict of interests.

**Acknowledgments**

The authors sincerely thanks go to Dr. Ashwin Patel and Dr. Prashant V. Acharya for referrals. They sincerely acknowledge Dr. Frenny Sheth for her valuable suggestions. This study was supported by ICMR Grants nos. 54/2/2005-BMS and 54/1/2009-BMS.

**References**

[1] S. Mohindroo, “Type-3 Gaucher disease with bilateral necrosis of the neck of femur: a case report,” *Cases Journal*, vol. 2, no. 12, article no. 9380, 2009.

[2] C. Drugan, L. Procopciuc, G. Jebeleanu et al., “Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations,” *European Journal of Human Genetics*, vol. 10, no. 9, pp. 511–515, 2002.

[3] P. Kaplan, H. C. Andersson, K. A. Kacena, and J. D. Yee, “The clinical and demographic characteristics of nonneuronopathic Gaucher Disease in 887 children at diagnosis,” *Archives of Pediatrics and Adolescent Medicine*, vol. 160, no. 6, pp. 603–608, 2006.

[4] C. R. Scrivener, A. L. Beaudet, W. S. Sly, and D. Valle, *The Metabolic and Molecular Basis of Inherited Disease*, vol. 2, McGraw-Hill, New York, NY, USA, 7th edition, 1995.

[5] J. J. Sheth, F. J. Sheth, N. J. Za, P. S. Gambhir, U. P. Dave, and R. C. Shah, “Plasma chitotriosidase activity in children with lysosomal storage disorders,” *Indian Journal of Pediatrics*, vol. 77, no. 2, pp. 203–205, 2010.

[6] R. G. Boot, G. H. Renkema, M. Verhock et al., “The human chitotriosidase gene—nature of inherited enzyme deficiency,” *Journal of Biological Chemistry*, vol. 273, no. 40, pp. 25680–25685, 1998.

[7] J. M. F. Aerts and C. E. M. Hollak, “Plasma and metabolic abnormalities in Gaucher’s disease,” *Bailliere’s Clinical Haematology*, vol. 10, no. 4, pp. 691–709, 1997.

[8] G. M. Pastores and D. A. Hughes, “Gaucher disease,” in *GeneReviews*, R. A. Pagon, T. D. Bird, C. R. Dolan, and K. Stephens, Eds., University of Washington, Seattle, Seattle, Wash, USA, 1993.

[9] M. Horowitz, G. Tzuri, N. Eyal et al., “Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease
patients,” *American Journal of Human Genetics*, vol. 53, no. 4, pp. 921–930, 1993.

[10] A. Uchiyama, S. Tomatsu, N. Kondo et al., “New Gaucher disease mutations in exon 10: a novel L444R mutation produces a new NciI site the same as L444P,” *Human Molecular Genetics*, vol. 3, no. 7, pp. 1183–1184, 1994.

[11] A. Zimran and D. Elstein, “Gaucher disease and the clinical experience with substrate reduction therapy,” *Philosophical Transactions of the Royal Society B*, vol. 358, no. 1433, pp. 961–966, 2003.